Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems.
Pyridine derivatives with one or more keto groups on the ring.
Therapy of heavy metal poisoning using agents which sequester the metal from organs or tissues and bind it firmly within the ring structure of a new compound which can be eliminated from the body.
An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)
A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent.
A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN.
Low-molecular-weight compounds produced by microorganisms that aid in the transport and sequestration of ferric iron. (The Encyclopedia of Molecular Biology, 1994)
A form of pneumoconiosis resulting from inhalation of iron in the mining dust or welding fumes.
Agents counteracting or neutralizing the action of POISONS.
Derivatives of BENZOIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxybenzene structure.
Inorganic compounds that contain the OH- group.
Highly reactive molecules with an unsatisfied electron valence pair. Free radicals are produced in both normal and pathological processes. They are proven or suspected agents of tissue damage in a wide variety of circumstances including radiation, damage from environment chemicals, and aging. Natural and pharmacological prevention of free radical damage is being actively investigated.
Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS.
Iron-containing proteins that are widely distributed in animals, plants, and microorganisms. Their major function is to store IRON in a nontoxic bioavailable form. Each ferritin molecule consists of ferric iron in a hollow protein shell (APOFERRITINS) made of 24 subunits of various sequences depending on the species and tissue types.
The univalent radical OH. Hydroxyl radical is a potent oxidizing agent.
Conditions in which there is a generalized increase in the iron stores of body tissues, particularly of liver and the MONONUCLEAR PHAGOCYTE SYSTEM, without demonstrable tissue damage. The name refers to the presence of stainable iron in the tissue in the form of hemosiderin.
Bleeding into one or both CEREBRAL HEMISPHERES due to TRAUMA. Hemorrhage may involve any part of the CEREBRAL CORTEX and the BASAL GANGLIA. Depending on the severity of bleeding, clinical features may include SEIZURES; APHASIA; VISION DISORDERS; MOVEMENT DISORDERS; PARALYSIS; and COMA.
Triazoles are a class of antifungal drugs that contain a triazole ring in their chemical structure and work by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting the integrity and function of the membrane.
A strong oxidizing agent used in aqueous solution as a ripening agent, bleach, and topical anti-infective. It is relatively unstable and solutions deteriorate over time unless stabilized by the addition of acetanilide or similar organic materials.
Unstable isotopes of iron that decay or disintegrate emitting radiation. Fe atoms with atomic weights 52, 53, 55, and 59-61 are radioactive iron isotopes.
The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed)
A complex of ferric oxyhydroxide with dextrans of 5000 to 7000 daltons in a viscous solution containing 50 mg/ml of iron. It is supplied as a parenteral preparation and is used as a hematinic. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1292)
An iron-binding beta1-globulin that is synthesized in the LIVER and secreted into the blood. It plays a central role in the transport of IRON throughout the circulation. A variety of transferrin isoforms exist in humans, including some that are considered markers for specific disease states.
Substances that influence the course of a chemical reaction by ready combination with free radicals. Among other effects, this combining activity protects pancreatic islets against damage by cytokines and prevents myocardial and pulmonary perfusion injuries.
Inorganic or organic compounds containing trivalent iron.
Starches that have been chemically modified so that a percentage of OH groups are substituted with 2-hydroxyethyl ether groups.
A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia.
Procedures concerned with the remedial treatment or prevention of diseases.
A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.
A genus of the family CEBIDAE, subfamily CEBINAE, consisting of four species which are divided into two groups, the tufted and untufted. C. apella has tufts of hair over the eyes and sides of the head. The remaining species are without tufts - C. capucinus, C. nigrivultatus, and C. albifrons. Cebus inhabits the forests of Central and South America.
3-Hydroxy-4-oxo-1(4H)-pyridinealanine. An antineoplastic alanine-substituted pyridine derivative isolated from Leucena glauca.
Membrane glycoproteins found in high concentrations on iron-utilizing cells. They specifically bind iron-bearing transferrin, are endocytosed with its ligand and then returned to the cell surface where transferrin without its iron is released.
A reagent used for the determination of iron.
An oxidoreductase that catalyzes the conversion of HYDROGEN PEROXIDE to water and oxygen. It is present in many animal cells. A deficiency of this enzyme results in ACATALASIA.
Electron-accepting molecules in chemical reactions in which electrons are transferred from one molecule to another (OXIDATION-REDUCTION).
Molecules or ions formed by the incomplete one-electron reduction of oxygen. These reactive oxygen intermediates include SINGLET OXYGEN; SUPEROXIDES; PEROXIDES; HYDROXYL RADICAL; and HYPOCHLOROUS ACID. They contribute to the microbicidal activity of PHAGOCYTES, regulation of signal transduction and gene expression, and the oxidative damage to NUCLEIC ACIDS; PROTEINS; and LIPIDS.
Inorganic or organic compounds that contain divalent iron.

The effect of chelating agents on iron mobilization in Chang cell cultures. (1/1100)

The investigation of chelating agents with potential therapeutic value in patients with transfusional iron overload has been facilitated by the use of Chang cell cultures. These cells have been incubated with [59Fe]transferrin for 22 hr, following which most of the intracellular radioiron is found in the cytosol, distributed between a ferritin and a nonferritin form. Iron release from the cells depends on transferrin saturation in the medium, but when transferrin is 100% saturated, which normally does not allow iron release, desferrioxamine, 2,3-dihydroxybenzoic acid, rhodotorulic acid, cholythydroxamic acid, and tropolone all promote the mobilization of ferritin iron and its release from cells. They are effective to an approximately equal degree. The incubation of [59Fe]transferrin with tropolone in vitro at a molar ratio of 1:500 results in the transfer of most of the labeled iron to the chelator, reflecting the exceptionally high binding constant of this compound. How far these phenomena relate to therapeutic potentially remains to be seen.  (+info)

Hereditary juvenile haemochromatosis: a genetically heterogeneous life-threatening iron-storage disease. (2/1100)

Juvenile haemochromatosis is a rare inborn error of iron metabolism with clinical manifestations before 30 years of age. Unlike adult haemochromatosis which principally affects men, juvenile haemochromatosis affects the sexes equally; it causes early endocrine failure, dilated cardiomyopathy and joint disease. We report four patients (two of each sex) from three pedigrees affected by juvenile haemochromatosis with a mean onset at 22 years (range 14-30). All had endocrine deficiency with postpubertal gonadal failure secondary to pituitary disease; two suffered near-fatal cardiomyopathy with heart failure. Mean time to diagnosis from the first clinical signs of disease was 9.8 years (range 0.5-20) but general health and parameters of iron storage responded favourably to iron-depletion therapy. A 24-year-old man listed for heart transplantation because of cardiomyopathy [left ventricular (LV) ejection fraction 16%] responded to intravenous iron chelation with desferrioxamine combined with phlebotomy (ejection fraction 31%). A 27-year-old woman with subacute biventricular heart failure refractory to medication required orthotopic cardiac transplantation before the diagnosis was established (LV ejection fraction 25%). Genetic studies showed that these two patients with cardiomyopathy from unrelated families were heterozygous for the HFE 845G-->A (C282Y) mutation and wild-type at the H63D locus: complete sequencing of the intron-exon boundaries and entire coding sequence of the HFE gene failed to identify additional lesions. Two siblings in a pedigree without cardiomyopathy were wild-type at the HFE C282Y locus; although the brother harboured a single copy of the 187C-->G (H63D) allele, segregation analysis showed that in neither sibling was the iron-storage disease linked to MHC Class I markers on chromosome 6p. Juvenile haemochromatosis is thus a genetically heterogenous disorder distinct from the common adult variant.  (+info)

Down regulation by iron of prostaglandin E2 production by human synovial fibroblasts. (3/1100)

OBJECTIVE: To examine the effect of iron on the prostaglandin (PG) E2 production by human synovial fibroblasts in vitro. METHODS: Human synovial fibroblasts were isolated from synovial tissue of rheumatoid arthritis (RA) and osteoarthritis (OA) patients and cultured in medium. Synovial fibroblasts were stimulated by human recombinant interleukin (IL) 1 beta (0.1-10 ng/ml) with or without ferric citrate (Fe-citrate, 0.01-1 mM). The amount of PGE2 in the culture medium was measured by an enzyme linked immunosorbent assay. RESULTS: The production of PGE2 by the synovial fibroblasts was increased by stimulation with IL1 beta at all concentrations tested. Fe-citrate but not sodium citrate (Na-citrate) down regulated the production of PGE2 by the synovial fibroblasts, both with and without stimulation by IL1 beta. Fe-citrate inhibited the spontaneous PGE2 production by the cells in a dose dependent manner, and a maximum inhibition by Fe-citrate was observed at the concentration of 0.1 mM with IL1 beta stimulation. The down regulation by iron was reversed by the co-addition of desferrioxamine (100 micrograms/ml), an iron chelator. CONCLUSION: Iron down regulates the PGE2 production by synovial fibroblasts in vitro.  (+info)

Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. (4/1100)

It has been proposed that cells sense hypoxia by a heme protein, which transmits a signal that activates the heterodimeric transcription factor hypoxia-inducible factor 1 (HIF-1), thereby inducing a number of physiologically relevant genes such as erythropoietin (Epo). We have investigated the mechanism by which two heme-binding ligands, carbon monoxide and nitric oxide, affect oxygen sensing and signaling. Two concentrations of CO (10 and 80%) suppressed the activation of HIF-1 and induction of Epo mRNA by hypoxia in a dose-dependent manner. In contrast, CO had no effect on the induction of HIF-1 activity and Epo expression by either cobalt chloride or the iron chelator desferrioxamine. The affinity of CO for the putative sensor was much lower than that of oxygen (Haldane coefficient, approximately 0.5). Parallel experiments were done with 100 microM sodium nitroprusside, a nitric oxide donor. Both NO and CO inhibited HIF-1 DNA binding by abrogating hypoxia-induced accumulation of HIF-1alpha protein. Moreover, both NO and CO specifically targeted the internal oxygen-dependent degradation domain of HIF-1alpha, and also repressed the C-terminal transactivation domain of HIF-1alpha. Thus, NO and CO act proximally, presumably as heme ligands binding to the oxygen sensor, whereas desferrioxamine and perhaps cobalt appear to act at a site downstream.  (+info)

IC202A, a new siderophore with immunosuppressive activity produced by Streptoalloteichus sp. 1454-19. I. Taxonomy, fermentation, isolation and biological activity. (5/1100)

IC202A, a new immunosuppressive compound, was isolated from the culture filtrate of Streptoalloteichus sp. 1454-19. It showed a suppressive effect on mixed lymphocyte culture reaction with an IC50 value of 3.6 microg/ml and mitogen induced lymphocyte blastogenesis in vitro.  (+info)

IC202A, a new siderophore with immunosuppressive activity produced by Streptoalloteichus sp. 1454-19. II. Physico-chemical properties and structure elucidation. (6/1100)

IC202A (1) was isolated from the culture filtrate of Streptoalloteichus sp. 1454-19. The structure of 1 was determined by spectral analysis including a variety of two-dimentional NMR and FAB-MS experiments. IC202A is a ferrioxamine-related compound containing a butylidene N-oxide function.  (+info)

Ferrioxamine-mediated Iron(III) utilization by Salmonella enterica. (7/1100)

Utilization of ferrioxamines as sole sources of iron distinguishes Salmonella enterica serotypes Typhimurium and Enteritidis from a number of related species, including Escherichia coli. Ferrioxamine supplements have therefore been used in preenrichment and selection media to increase the bacterial growth rate while selectivity is maintained. We characterized the determinants involved in utilization of ferrioxamines B, E, and G by S. enterica serotype Typhimurium by performing siderophore cross-feeding bioassays. Transport of all three ferric siderophores across the outer membrane was dependent on the FoxA receptor encoded by the Fur-repressible foxA gene. However, only the transport of ferrioxamine G was dependent on the energy-transducing protein TonB, since growth stimulation of a tonB strain by ferrioxamines B and E was observed, albeit at lower efficiencies than in the parental strain. Transport across the inner membrane was dependent on the periplasmic binding protein-dependent ABC transporter complex comprising FhuBCD, as has been reported for other hydroxamate siderophores of enteric bacteria. The distribution of the foxA gene in the genus Salmonella, as indicated by DNA hybridization studies and correlated with the ability to utilize ferrioxamine E, was restricted to subspecies I, II, and IIIb, and this gene was absent from subspecies IIIa, IV, VI, and VII (formerly subspecies IV) and Salmonella bongori (formerly subspecies V). S. enterica serotype Typhimurium mutants with either a transposon insertion or a defined nonpolar frameshift (+2) mutation in the foxA gene were not able to utilize any of the three ferrioxamines tested. A strain carrying the nonpolar foxA mutation exhibited a significantly reduced ability to colonize rabbit ileal loops compared to the foxA+ parent. In addition, a foxA mutant was markedly attenuated in mice inoculated by either the intragastric or intravenous route. Mice inoculated with the foxA mutant were protected against subsequent challenge by the foxA+ parent strain.  (+info)

The iron regulatory protein can determine the effectiveness of 5-aminolevulinic acid in inducing protoporphyrin IX in human primary skin fibroblasts. (8/1100)

The level of endogenous photosensitiser, protoporphyrin IX (PPIX), can be enhanced in the cells by 5-aminolevulinic acid (ALA). We investigated the effect of critical parameters such as growth state of the cells and availability of intracellular iron in modulating the level of PPIX, in human primary cultured skin fibroblasts (FEK4) maintained either in exponentially growing or growth-arrested phase, following treatment with ALA. The addition of ALA to exponentially growing cells increased the level of PPIX 6-fold relative to control cells; however, in growth-arrested cells the same treatment increased the level of PPIX up to 34-fold. The simultaneous addition of the hydrophilic iron-chelator Desferal with ALA, boosted the level of PPIX up to 47-fold in growing cells and up to 42-fold in growth-arrested cells, suggesting that iron is limiting under the latter conditions. The strict dependence of PPIX enhancement on free available iron levels was examined by the level of activation of iron regulatory protein in band shift assays. This analysis revealed that the basal level of iron regulatory protein in growth-arrested cells was 6-fold higher than in growing cells, reflecting the influence of the free available iron pool in exponentially growing cells. Interestingly, the same ratio was found between the basal level concentration of PPIX in growing and growth-arrested cells. We propose that iron regulatory protein activation could serve as a marker for developing photodynamic therapy protocols because it identifies cells and tissues with a propensity to accumulate PPIX and it is therefore likely to predict the effectiveness of such therapies.  (+info)

Deferoxamine is a medication used to treat iron overload, which can occur due to various reasons such as frequent blood transfusions or excessive iron intake. It works by binding to excess iron in the body and promoting its excretion through urine. This helps to prevent damage to organs such as the heart and liver that can be caused by high levels of iron.

Deferoxamine is an injectable medication that is typically administered intravenously or subcutaneously, depending on the specific regimen prescribed by a healthcare professional. It may also be used in combination with other medications to manage iron overload more effectively.

It's important to note that deferoxamine should only be used under the guidance of a medical professional, as improper use or dosing can lead to serious side effects or complications.

Iron chelating agents are medications that bind to iron in the body, forming a stable complex that can then be excreted from the body. These agents are primarily used to treat iron overload, a condition that can occur due to frequent blood transfusions or certain genetic disorders such as hemochromatosis. By reducing the amount of iron in the body, these medications can help prevent or reduce damage to organs such as the heart and liver. Examples of iron chelating agents include deferoxamine, deferasirox, and deferiprone.

Pyridones are a class of organic compounds that contain a pyridone ring, which is a heterocyclic ring consisting of a six-membered ring with five carbon atoms and one nitrogen atom, with one oxygen atom attached to the nitrogen atom by a double bond. Pyridones can be found in various natural sources, including plants and microorganisms, and they also have important applications in the pharmaceutical industry as building blocks for drug design and synthesis. Some drugs that contain pyridone rings include antihistamines, anti-inflammatory agents, and antiviral agents.

Chelation therapy is a medical treatment that involves the use of chelating agents to remove heavy metals and minerals from the body. A chelating agent is a molecule that bonds with the metal ions, forming a stable, water-soluble complex that can be excreted through urine or stool.

The most common chelating agent used in medical settings is ethylene diamine tetraacetic acid (EDTA), which is administered intravenously. EDTA binds with metals such as lead, mercury, iron, and calcium, and helps to eliminate them from the body.

Chelation therapy is primarily used to treat heavy metal poisoning, such as lead or mercury toxicity. It may also be used in some cases to treat cardiovascular disease, although its effectiveness for this use is still a matter of debate and controversy.

It's important to note that chelation therapy should only be administered under the supervision of a qualified healthcare professional, as improper use can lead to serious side effects and complications.

Iron overload is a condition characterized by an excessive accumulation of iron in the body's tissues and organs, particularly in the liver, heart, and pancreas. This occurs when the body absorbs more iron than it can use or eliminate, leading to iron levels that are higher than normal.

Iron overload can result from various factors, including hereditary hemochromatosis, a genetic disorder that affects how the body absorbs iron from food; frequent blood transfusions, which can cause iron buildup in people with certain chronic diseases such as sickle cell anemia or thalassemia; and excessive consumption of iron supplements or iron-rich foods.

Symptoms of iron overload may include fatigue, joint pain, abdominal discomfort, irregular heartbeat, and liver dysfunction. If left untreated, it can lead to serious complications such as cirrhosis, liver failure, diabetes, heart problems, and even certain types of cancer. Treatment typically involves regular phlebotomy (removal of blood) to reduce iron levels in the body, along with dietary modifications and monitoring by a healthcare professional.

Beta-thalassemia is a genetic blood disorder that affects the production of hemoglobin, a protein in red blood cells that carries oxygen throughout the body. Specifically, beta-thalassemia is caused by mutations in the beta-globin gene, which leads to reduced or absent production of the beta-globin component of hemoglobin.

There are two main types of beta-thalassemia:

1. Beta-thalassemia major (also known as Cooley's anemia): This is a severe form of the disorder that typically becomes apparent in early childhood. It is characterized by a significant reduction or absence of beta-globin production, leading to anemia, enlarged spleen and liver, jaundice, and growth retardation.
2. Beta-thalassemia intermedia: This is a milder form of the disorder that may not become apparent until later in childhood or even adulthood. It is characterized by a variable reduction in beta-globin production, leading to mild to moderate anemia and other symptoms that can range from nonexistent to severe.

Treatment for beta-thalassemia depends on the severity of the disorder and may include blood transfusions, iron chelation therapy, and/or bone marrow transplantation. In some cases, genetic counseling and prenatal diagnosis may also be recommended for families with a history of the disorder.

In the context of medicine, iron is an essential micromineral and key component of various proteins and enzymes. It plays a crucial role in oxygen transport, DNA synthesis, and energy production within the body. Iron exists in two main forms: heme and non-heme. Heme iron is derived from hemoglobin and myoglobin in animal products, while non-heme iron comes from plant sources and supplements.

The recommended daily allowance (RDA) for iron varies depending on age, sex, and life stage:

* For men aged 19-50 years, the RDA is 8 mg/day
* For women aged 19-50 years, the RDA is 18 mg/day
* During pregnancy, the RDA increases to 27 mg/day
* During lactation, the RDA for breastfeeding mothers is 9 mg/day

Iron deficiency can lead to anemia, characterized by fatigue, weakness, and shortness of breath. Excessive iron intake may result in iron overload, causing damage to organs such as the liver and heart. Balanced iron levels are essential for maintaining optimal health.

Siderophores are low-molecular-weight organic compounds that are secreted by microorganisms, such as bacteria and fungi, to chelate and solubilize iron from their environment. They are able to bind ferric iron (Fe3+) with very high affinity and form a siderophore-iron complex, which can then be taken up by the microorganism through specific transport systems. This allows them to acquire iron even in environments where it is present at very low concentrations or in forms that are not readily available for uptake. Siderophores play an important role in the survival and virulence of many pathogenic microorganisms, as they help them to obtain the iron they need to grow and multiply.

Siderosis is a medical condition characterized by the abnormal accumulation of iron in various tissues and organs, most commonly in the lungs. This occurs due to the repeated inhalation of iron-containing dusts or fumes, which can result from certain industrial processes such as welding, mining, or smelting.

In the lungs, this iron deposit can lead to inflammation and fibrosis, potentially causing symptoms like coughing, shortness of breath, and decreased lung function. It is important to note that siderosis itself is not contagious or cancerous, but there may be an increased risk for lung cancer in individuals with severe and prolonged exposure to iron-containing particles.

While siderosis is generally non-reversible, the progression of symptoms can often be managed through medical interventions and environmental modifications to reduce further exposure to iron-containing dusts or fumes.

An antidote is a substance that can counteract the effects of a poison or toxin. It works by neutralizing, reducing, or eliminating the harmful effects of the toxic substance. Antidotes can be administered in various forms such as medications, vaccines, or treatments. They are often used in emergency situations to save lives and prevent serious complications from poisoning.

The effectiveness of an antidote depends on several factors, including the type and amount of toxin involved, the timing of administration, and the individual's response to treatment. In some cases, multiple antidotes may be required to treat a single poisoning incident. It is important to note that not all poisons have specific antidotes, and in such cases, supportive care and symptomatic treatment may be necessary.

Examples of common antidotes include:

* Naloxone for opioid overdose
* Activated charcoal for certain types of poisoning
* Digoxin-specific antibodies for digoxin toxicity
* Fomepizole for methanol or ethylene glycol poisoning
* Dimercaprol for heavy metal poisoning.

Benzoates are the salts and esters of benzoic acid. They are widely used as preservatives in foods, cosmetics, and pharmaceuticals to prevent the growth of microorganisms. The chemical formula for benzoic acid is C6H5COOH, and when it is combined with a base (like sodium or potassium), it forms a benzoate salt (e.g., sodium benzoate or potassium benzoate). When benzoic acid reacts with an alcohol, it forms a benzoate ester (e.g., methyl benzoate or ethyl benzoate).

Benzoates are generally considered safe for use in food and cosmetics in small quantities. However, some people may have allergies or sensitivities to benzoates, which can cause reactions such as hives, itching, or asthma symptoms. In addition, there is ongoing research into the potential health effects of consuming high levels of benzoates over time, particularly in relation to gut health and the development of certain diseases.

In a medical context, benzoates may also be used as a treatment for certain conditions. For example, sodium benzoate is sometimes given to people with elevated levels of ammonia in their blood (hyperammonemia) to help reduce those levels and prevent brain damage. This is because benzoates can bind with excess ammonia in the body and convert it into a form that can be excreted in urine.

Hydroxides are inorganic compounds that contain the hydroxide ion (OH−). They are formed when a base, which is an electron pair donor, reacts with water. The hydroxide ion consists of one oxygen atom and one hydrogen atom, and it carries a negative charge. Hydroxides are basic in nature due to their ability to donate hydroxide ions in solution, which increases the pH and makes the solution more alkaline. Common examples of hydroxides include sodium hydroxide (NaOH), potassium hydroxide (KOH), and calcium hydroxide (Ca(OH)2). They have various applications in industry, medicine, and research.

Free radicals are molecules or atoms that have one or more unpaired electrons in their outermost shell, making them highly reactive. They can be formed naturally in the body through processes such as metabolism and exercise, or they can come from external sources like pollution, radiation, and certain chemicals. Free radicals can cause damage to cells and contribute to the development of various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. Antioxidants are substances that can neutralize free radicals and help protect against their harmful effects.

Chelating agents are substances that can bind and form stable complexes with certain metal ions, preventing them from participating in chemical reactions. In medicine, chelating agents are used to remove toxic or excessive amounts of metal ions from the body. For example, ethylenediaminetetraacetic acid (EDTA) is a commonly used chelating agent that can bind with heavy metals such as lead and mercury, helping to eliminate them from the body and reduce their toxic effects. Other chelating agents include dimercaprol (BAL), penicillamine, and deferoxamine. These agents are used to treat metal poisoning, including lead poisoning, iron overload, and copper toxicity.

Ferritin is a protein in iron-metabolizing cells that stores iron in a water-soluble form. It is found inside the cells (intracellular) and is released into the bloodstream when the cells break down or die. Measuring the level of ferritin in the blood can help determine the amount of iron stored in the body. High levels of ferritin may indicate hemochromatosis, inflammation, liver disease, or other conditions. Low levels of ferritin may indicate anemia, iron deficiency, or other conditions.

A hydroxyl radical is defined in biochemistry and medicine as an extremely reactive species, characterized by the presence of an oxygen atom bonded to a hydrogen atom (OH-). It is formed when a water molecule (H2O) is split into a hydroxide ion (OH-) and a hydrogen ion (H+) in the process of oxidation.

In medical terms, hydroxyl radicals are important in understanding free radical damage and oxidative stress, which can contribute to the development of various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. They are also involved in the body's natural defense mechanisms against pathogens. However, an overproduction of hydroxyl radicals can cause damage to cellular components such as DNA, proteins, and lipids, leading to cell dysfunction and death.

Hemosiderosis is a medical condition characterized by the abnormal accumulation of hemosiderin, an iron-containing protein, in various organs and tissues of the body. Hemosiderin is derived from the breakdown of hemoglobin, which is the oxygen-carrying protein in red blood cells. When there is excessive breakdown of red blood cells or impaired clearance of hemosiderin, it can lead to its accumulation in organs such as the liver, spleen, and lungs.

Hemosiderosis can be classified into two types: primary and secondary. Primary hemosiderosis is a rare condition that is caused by genetic disorders affecting red blood cells, while secondary hemosiderosis is more common and is associated with various conditions that cause excessive breakdown of red blood cells or chronic inflammation. These conditions include hemolytic anemias, repeated blood transfusions, liver diseases, infections, and certain autoimmune disorders.

The accumulation of hemosiderin can lead to tissue damage and organ dysfunction, particularly in the lungs, where it can cause pulmonary fibrosis, and in the heart, where it can lead to heart failure. Hemosiderosis is typically diagnosed through a combination of medical history, physical examination, and laboratory tests, including blood tests and imaging studies such as chest X-rays or MRI scans. Treatment of hemosiderosis depends on the underlying cause and may include medications, blood transfusions, or supportive care to manage symptoms and prevent complications.

A traumatic cerebral hemorrhage is a type of brain injury that results from a trauma or external force to the head, which causes bleeding in the brain. This condition is also known as an intracranial hemorrhage or epidural or subdural hematoma, depending on the location and extent of the bleeding.

The trauma can cause blood vessels in the brain to rupture, leading to the accumulation of blood in the skull and increased pressure on the brain. This can result in various symptoms such as headache, confusion, seizures, vomiting, weakness or numbness in the limbs, loss of consciousness, and even death if not treated promptly.

Traumatic cerebral hemorrhage is a medical emergency that requires immediate attention and treatment. Treatment options may include surgery to relieve pressure on the brain, medication to control seizures and reduce swelling, and rehabilitation to help with recovery. The prognosis for traumatic cerebral hemorrhage depends on various factors such as the severity of the injury, location of the bleeding, age and overall health of the patient, and timeliness of treatment.

Triazoles are a class of antifungal medications that have broad-spectrum activity against various fungi, including yeasts, molds, and dermatophytes. They work by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, leading to increased permeability and disruption of fungal growth. Triazoles are commonly used in both systemic and topical formulations for the treatment of various fungal infections, such as candidiasis, aspergillosis, cryptococcosis, and dermatophytoses. Some examples of triazole antifungals include fluconazole, itraconazole, voriconazole, and posaconazole.

Hydrogen peroxide (H2O2) is a colorless, odorless, clear liquid with a slightly sweet taste, although drinking it is harmful and can cause poisoning. It is a weak oxidizing agent and is used as an antiseptic and a bleaching agent. In diluted form, it is used to disinfect wounds and kill bacteria and viruses on the skin; in higher concentrations, it can be used to bleach hair or remove stains from clothing. It is also used as a propellant in rocketry and in certain industrial processes. Chemically, hydrogen peroxide is composed of two hydrogen atoms and two oxygen atoms, and it is structurally similar to water (H2O), with an extra oxygen atom. This gives it its oxidizing properties, as the additional oxygen can be released and used to react with other substances.

"Iron radioisotopes" refer to specific forms of the element iron that have unstable nuclei and emit radiation. These isotopes are often used in medical imaging and treatment procedures due to their ability to be detected by specialized equipment. Common iron radioisotopes include Iron-52, Iron-55, Iron-59, and Iron-60. They can be used as tracers to study the distribution, metabolism, or excretion of iron in the body, or for targeted radiation therapy in conditions such as cancer.

A blood transfusion is a medical procedure in which blood or its components are transferred from one individual (donor) to another (recipient) through a vein. The donated blood can be fresh whole blood, packed red blood cells, platelets, plasma, or cryoprecipitate, depending on the recipient's needs. Blood transfusions are performed to replace lost blood due to severe bleeding, treat anemia, support patients undergoing major surgeries, or manage various medical conditions such as hemophilia, thalassemia, and leukemia. The donated blood must be carefully cross-matched with the recipient's blood type to minimize the risk of transfusion reactions.

Iron-dextran complex is a parenteral preparation used as an iron supplement to treat or prevent iron deficiency anemia in patients who cannot take oral iron or do not respond well to oral iron therapy. The complex is formed by combining iron salts with dextran, a type of polysaccharide derived from cornstarch, which acts as a carrier and helps increase the solubility and stability of the iron.

The iron-dextran complex is available in various forms, including injectable solutions and intravenous (IV) infusions. It works by releasing iron ions slowly into the body, where they can be taken up by red blood cell precursors in the bone marrow and used to synthesize hemoglobin, a protein that carries oxygen in the blood.

It is important to note that iron-dextran complex can cause anaphylactic reactions in some individuals, so it should be administered with caution and under medical supervision. Patients should be monitored for signs of allergic reactions during and after administration, and appropriate measures should be taken if necessary.

Transferrin is a glycoprotein that plays a crucial role in the transport and homeostasis of iron in the body. It's produced mainly in the liver and has the ability to bind two ferric (Fe3+) ions in its N-lobe and C-lobe, thus creating transferrin saturation.

This protein is essential for delivering iron to cells while preventing the harmful effects of free iron, which can catalyze the formation of reactive oxygen species through Fenton reactions. Transferrin interacts with specific transferrin receptors on the surface of cells, particularly in erythroid precursors and brain endothelial cells, to facilitate iron uptake via receptor-mediated endocytosis.

In addition to its role in iron transport, transferrin also has antimicrobial properties due to its ability to sequester free iron, making it less available for bacterial growth and survival. Transferrin levels can be used as a clinical marker of iron status, with decreased levels indicating iron deficiency anemia and increased levels potentially signaling inflammation or liver disease.

Free radical scavengers, also known as antioxidants, are substances that neutralize or stabilize free radicals. Free radicals are highly reactive atoms or molecules with unpaired electrons, capable of causing damage to cells and tissues in the body through a process called oxidative stress. Antioxidants donate an electron to the free radical, thereby neutralizing it and preventing it from causing further damage. They can be found naturally in foods such as fruits, vegetables, and nuts, or they can be synthesized and used as dietary supplements. Examples of antioxidants include vitamins C and E, beta-carotene, and selenium.

Ferric compounds are inorganic compounds that contain the iron(III) cation, Fe3+. Iron(III) is a transition metal and can form stable compounds with various anions. Ferric compounds are often colored due to the d-d transitions of the iron ion. Examples of ferric compounds include ferric chloride (FeCl3), ferric sulfate (Fe2(SO4)3), and ferric oxide (Fe2O3). Ferric compounds have a variety of uses, including as catalysts, in dye production, and in medical applications.

Hydroxyethyl starch derivatives are modified starches that are used as plasma expanders in medicine. They are created by chemically treating corn, potato, or wheat starch with hydroxylethyl groups, which makes the starch more soluble and less likely to be broken down by enzymes in the body. This results in a large molecule that can remain in the bloodstream for an extended period, increasing intravascular volume and improving circulation.

These derivatives are available in different molecular weights and substitution patterns, which affect their pharmacokinetics and pharmacodynamics. They are used to treat or prevent hypovolemia (low blood volume) due to various causes such as bleeding, burns, or dehydration. Common brand names include Hetastarch, Pentastarch, and Voluven.

It's important to note that the use of hydroxyethyl starch derivatives has been associated with adverse effects, including kidney injury, coagulopathy, and pruritus (severe itching). Therefore, their use should be carefully monitored and restricted to specific clinical situations.

Thalassemia is a group of inherited genetic disorders that affect the production of hemoglobin, a protein in red blood cells responsible for carrying oxygen throughout the body. The disorder results in less efficient or abnormal hemoglobin, which can lead to anemia, an insufficient supply of oxygen-rich red blood cells.

There are two main types of Thalassemia: alpha and beta. Alpha thalassemia occurs when there is a problem with the alpha globin chain production, while beta thalassemia results from issues in beta globin chain synthesis. These disorders can range from mild to severe, depending on the number of genes affected and their specific mutations.

Severe forms of Thalassemia may require regular blood transfusions, iron chelation therapy, or even a bone marrow transplant to manage symptoms and prevent complications.

Therapeutics, in medical terms, refers to the branch of medicine concerned with the treatment of diseases and the action or process of treating patients medically. It involves the use of various substances, physical treatments, or psychological methods to prevent, alleviate, or cure a disease, injury, or other medical condition. This may include the use of medications, surgery, radiation, chemotherapy, immunotherapy, gene therapy, and other forms of treatment. The goal of therapeutics is to improve the patient's quality of life, reduce symptoms, and slow or stop the progression of a disease.

The chemical element aluminum (or aluminium in British English) is a silvery-white, soft, non-magnetic, ductile metal. The atomic number of aluminum is 13 and its symbol on the periodic table is Al. It is the most abundant metallic element in the Earth's crust and is found in a variety of minerals such as bauxite.

Aluminum is resistant to corrosion due to the formation of a thin layer of aluminum oxide on its surface that protects it from further oxidation. It is lightweight, has good thermal and electrical conductivity, and can be easily formed and machined. These properties make aluminum a widely used metal in various industries such as construction, packaging, transportation, and electronics.

In the medical field, aluminum is used in some medications and medical devices. For example, aluminum hydroxide is commonly used as an antacid to neutralize stomach acid and treat heartburn, while aluminum salts are used as adjuvants in vaccines to enhance the immune response. However, excessive exposure to aluminum can be harmful and has been linked to neurological disorders such as Alzheimer's disease, although the exact relationship between aluminum and these conditions is not fully understood.

"Cebus" is a genus of New World monkeys, also known as capuchin monkeys. They are small to medium-sized primates that are native to Central and South America. Capuchin monkeys are named after the Order of Friars Minor Capuchin, because of their similarity in color to the robes worn by the friars.

Capuchin monkeys are highly intelligent and social animals, living in groups of up to 30 individuals. They have a diverse diet that includes fruits, nuts, seeds, insects, and small vertebrates. Capuchin monkeys are known for their problem-solving abilities and have been observed using tools in the wild.

There are several species of capuchin monkeys, including the white-fronted capuchin (Cebus albifrons), the tufted capuchin (Cebus apella), and the weeper capuchin (Cebus olivaceus). They vary in size, coloration, and behavior, but all share the characteristic cap of hair on their heads that gives them their name.

Mimosine is not a medical term per se, but it is a chemical compound that has been studied in the context of biomedical research. Mimosine is an alkaloid found in certain plants, including the mimosa tree (Leucaena leucocephala). It has been shown to have various biological activities, such as anti-proliferative and cytotoxic effects on certain types of cells. However, it is not a term that is commonly used in medical diagnoses or treatments.

In terms of its chemical structure, mimosine is an amino acid that contains a pyrrolidone ring with a hydroxyl group at the 3-position and a carboxylic acid group at the 2-position. It can inhibit certain enzymes involved in DNA replication and repair, which may contribute to its anti-proliferative effects.

It's worth noting that mimosine has been studied for its potential therapeutic benefits, such as its ability to inhibit the growth of cancer cells. However, more research is needed to determine its safety and efficacy in humans before it can be considered a viable treatment option.

Transferrin receptors are membrane-bound proteins found on the surface of many cell types, including red and white blood cells, as well as various tissues such as the liver, brain, and placenta. These receptors play a crucial role in iron homeostasis by regulating the uptake of transferrin, an iron-binding protein, into the cells.

Transferrin binds to two ferric ions (Fe3+) in the bloodstream, forming a complex known as holo-transferrin. This complex then interacts with the transferrin receptors on the cell surface, leading to endocytosis of the transferrin-receptor complex into the cell. Once inside the cell, the acidic environment within the endosome causes the release of iron ions from the transferrin molecule, which can then be transported into the cytoplasm for use in various metabolic processes.

After releasing the iron, the apo-transferrin (iron-free transferrin) is recycled back to the cell surface and released back into the bloodstream, where it can bind to more ferric ions and repeat the cycle. This process helps maintain appropriate iron levels within the body and ensures that cells have access to the iron they need for essential functions such as DNA synthesis, energy production, and oxygen transport.

In summary, transferrin receptors are membrane-bound proteins responsible for recognizing and facilitating the uptake of transferrin-bound iron into cells, playing a critical role in maintaining iron homeostasis within the body.

'2,2'-Dipyridyl is an organic compound with the formula (C5H4N)2. It is a bidentate chelating ligand, which means that it can form stable coordination complexes with many metal ions by donating both of its nitrogen atoms to the metal. This ability to form complexes makes '2,2'-Dipyridyl useful in various applications, including as a catalyst in chemical reactions and as a reagent in the analysis of metal ions.

The compound is a solid at room temperature and has a molecular weight of 108.13 g/mol. It is soluble in organic solvents such as ethanol, acetone, and dichloromethane, but is insoluble in water. '2,2'-Dipyridyl is synthesized by the reaction of pyridine with formaldehyde and hydrochloric acid.

In medical contexts, '2,2'-Dipyridyl may be used as a reagent in diagnostic tests to detect the presence of certain metal ions in biological samples. However, it is not itself a drug or therapeutic agent.

Catalase is a type of enzyme that is found in many living organisms, including humans. Its primary function is to catalyze the decomposition of hydrogen peroxide (H2O2) into water (H2O) and oxygen (O2). This reaction helps protect cells from the harmful effects of hydrogen peroxide, which can be toxic at high concentrations.

The chemical reaction catalyzed by catalase can be represented as follows:

H2O2 + Catalase → H2O + O2 + Catalase

Catalase is a powerful antioxidant enzyme that plays an important role in protecting cells from oxidative damage. It is found in high concentrations in tissues that produce or are exposed to hydrogen peroxide, such as the liver, kidneys, and erythrocytes (red blood cells).

Deficiency in catalase activity has been linked to several diseases, including cancer, neurodegenerative disorders, and aging. On the other hand, overexpression of catalase has been shown to have potential therapeutic benefits in various disease models, such as reducing inflammation and oxidative stress.

Medical definitions of "oxidants" refer to them as oxidizing agents or substances that can gain electrons and be reduced. They are capable of accepting electrons from other molecules in chemical reactions, leading to the production of oxidation products. In biological systems, oxidants play a crucial role in various cellular processes such as energy production and immune responses. However, an imbalance between oxidant and antioxidant levels can lead to a state of oxidative stress, which has been linked to several diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. Examples of oxidants include reactive oxygen species (ROS), such as superoxide anion, hydrogen peroxide, and hydroxyl radical, as well as reactive nitrogen species (RNS), such as nitric oxide and peroxynitrite.

Reactive Oxygen Species (ROS) are highly reactive molecules containing oxygen, including peroxides, superoxide, hydroxyl radical, and singlet oxygen. They are naturally produced as byproducts of normal cellular metabolism in the mitochondria, and can also be generated by external sources such as ionizing radiation, tobacco smoke, and air pollutants. At low or moderate concentrations, ROS play important roles in cell signaling and homeostasis, but at high concentrations, they can cause significant damage to cell structures, including lipids, proteins, and DNA, leading to oxidative stress and potential cell death.

Ferrous compounds are inorganic substances that contain iron (Fe) in its +2 oxidation state. The term "ferrous" is derived from the Latin word "ferrum," which means iron. Ferrous compounds are often used in medicine, particularly in the treatment of iron-deficiency anemia due to their ability to provide bioavailable iron to the body.

Examples of ferrous compounds include ferrous sulfate, ferrous gluconate, and ferrous fumarate. These compounds are commonly found in dietary supplements and multivitamins. Ferrous sulfate is one of the most commonly used forms of iron supplementation, as it has a high iron content and is relatively inexpensive.

It's important to note that ferrous compounds can be toxic in large doses, so they should be taken under the guidance of a healthcare professional. Overdose can lead to symptoms such as nausea, vomiting, diarrhea, abdominal pain, and potentially fatal consequences if left untreated.

Deferoxamine is a siderophore from the bacteria Streptomyces pilosus. Deferoxamine was approved for medical use in the United ... Chronic use of deferoxamine may cause ocular symptoms, growth retardation, local reactions and allergy. Deferoxamine is ... Deferoxamine (DFOA), also known as desferrioxamine and sold under the brand name Desferal, is a medication that binds iron and ... Deferoxamine is used to treat acute iron poisoning, especially in small children. This agent is also frequently used to treat ...
The National Institute of Standards and Technology (NIST) uses its best efforts to deliver a high quality copy of the Database and to verify that the data contained therein have been selected on the basis of sound scientific judgment. However, NIST makes no warranties to that effect, and NIST shall not be liable for any damage that may result from errors or omissions in the Database ...
DEFEROXAMINE (deferoxamine mesylate) injection, powder, lyophilized, for solution. NDC Code(s): 63323-597-10, 63323-599-30 * ... DEFEROXAMINE MESYLATE injection, powder, lyophilized, for solution. NDC Code(s): 47781-623-07, 47781-624-07 *Packager: Alvogen ... DEFEROXAMINE MESYLATE injection, powder, lyophilized, for solution. NDC Code(s): 60505-6236-6, 60505-6237-6 *Packager: Apotex ... DEFEROXAMINE MESYLATE injection, powder, lyophilized, for solution. NDC Code(s): 68083-172-01, 68083-173-01 *Packager: Gland ...
Indeed, secondary results favored deferoxamine over placebo and "leave open the possibility that deferoxamine might lead to ... "Were also exploring the possibility, if deferoxamine is safe, if it is something that can be added on to other ongoing studies ... "We found that it is futile to conduct a phase 3 trial with the anticipation that treatment with deferoxamine would improve ... Patients in both the deferoxamine and placebo groups, however, continued to improve past 90 days. "These data, together with ...
pills and estrogens Blood pressure drugs Cholesterol drugs Deferoxamine (removes excess iron from the body) Gout drugs ... ...
deferoxamine is also known as Tie Min Ships from China. ...
High-dose deferoxamine treatment [‎intravenous]‎ for thalassaemia patients with cardiac complications  Ghader, F.R.; Kousarian ... As a means to manage cardiac conditions, we determined the effects of high-dose intravenous [‎IV]‎ deferoxamine in 15 ... Browsing EMRO Journal Articles (‎EMHJ)‎ by Subject "Deferoxamine". 0-9. A. B. C. D. E. F. G. H. I. J. K. L. M. N. O. P. Q. R. S ...
Deferoxamine rarely causes serum aminotransferase elevations during therapy and has not been convincingly linked to instances ... Deferoxamine is a parenterally administered iron chelating agent used to treat transfusion related chronic iron overload. ... Deferoxamine-chelatable iron in hemochromatosis and other disorders of iron overload.[Mayo Clin Proc. 1978]. Deferoxamine- ... The mechanism of injury accounting for serum enzyme elevations during deferoxamine therapy is not known. Deferoxamine is ...
Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinsons model. Download ... Chronic Intranasal Deferoxamine Ameliorates Motor Defects and Pathology in the Α-synuclein rAAV Parkinsons Model. Exp Neurol. ... Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinsons model. Exp Neurol. ... Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinsons model.. Exp Neurol ...
Deferoxamine rarely causes serum aminotransferase elevations during therapy and has not been convincingly linked to instances ... Deferoxamine is a parenterally administered iron chelating agent used to treat transfusion related chronic iron overload. ... Deferoxamine No authors listed In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. ... Deferoxamine is a parenterally administered iron chelating agent used to treat transfusion related chronic iron overload. ...
Deferoxamine inhibitor is a medication that binds iron and aluminium. ...
Intravenous infusions of deferoxamine mesylate may be associated with a pulmonary syndrome with features of a hypersensitivity ... Intravenous infusions of deferoxamine mesylate may be associated with a pulmonary syndrome with features of a hypersensitivity ...
Get up-to-date information on Deferoxamine side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about ... Deferoxamine is a prescription medication used to remove excess iron from the body. Deferoxamine belongs to a group of drugs ... Deferoxamine can also cause dizziness. Do not drive or operate heavy machinery until you know how deferoxamine affects you. ... How was your experience with Deferoxamine?. First, a little about yourself. Male Female ...
Deferoxamine. Lee et al, 2008. Diquat. Anton et al, 2002. 2,4-dinitrofluorobenzene. Cruz et al, 2002. ...
Deferoxamine [‎1]‎. Deficiency Diseases [‎1]‎. Dehydroepiandrosterone [‎1]‎. Delayed Diagnosis [‎3]‎. Delivery of Health Care ...
Administration of deferoxamine for the treatment of chronic iron overload.. *Administration of chemotherapy for the treatment ...
Intracerebral Hemorrhage Deferoxamine Trial - iDEF Trial. Magdy Selim, MD. Intracerebral Hemorrhage. Stroke. Interventional ...
Deferoxamine mesylate (DFO) is a drug approved by the FDA that is safe, has antioxidant effects, and can promote angiogenesis. ... Deferoxamine Mesylate Improves the Survival Rate of Transplanted Fat by Promoting Angiogen ... Deferoxamine Mesylate Improves the Survival Rate of Transplanted Fat by Promoting Angiogenesis. ...
... iron in beta-thalassaemia patients with myocardial siderosis previously chelated with deferoxamine monotherapy or deferoxamine- ... iron in beta-thalassaemia patients with myocardial siderosis previously chelated with deferoxamine monotherapy or deferoxamine- ...
In β-thalassemia major patients with severe iron burden, deferasirox was noninferior to deferoxamine for myocardial iron ... Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. ... A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on ... A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major ( ...
Badylak, S. F., & Babbs, C. F. (1986). The effect of carbon dioxide, lidoflazine and deferoxamine upon long term survival ... Badylak, Stephen F. ; Babbs, Charles F. / The effect of carbon dioxide, lidoflazine and deferoxamine upon long term survival ... Badylak, SF & Babbs, CF 1986, The effect of carbon dioxide, lidoflazine and deferoxamine upon long term survival following ... The effect of carbon dioxide, lidoflazine and deferoxamine upon long term survival following cardiorespiratory arrest in rats. ...
A serum iron test measures how much iron is in your blood.
deferoxamine An iron-chelating agent that removes iron from tumors by inhibiting DNA synthesis and causing cancer cell death. ...
Deferoxamine is an efficient iron chelator. It is administered as a prolonged infusion intravenously or subcutaneously for 5-7 ... Unlike deferasirox and deferoxamine, it selectively removes cardiac iron; is most effective when used in combination with ... Deferasirox has a capacity similar to deferoxamine in chelating iron, but it is administered orally. Renal toxicity might be a ...
Deferoxamine-derived metabolites. ↓ Carnitine C9:1, carnitine C12:1-OH, phenylacetylglutamine**. *. Busulfan metabolism is ...
Metal chelators, EDTA, diethylenetriaminepentaacetic acid, deferoxamine, and 1,10-phenanthroline inhibited .OH radical ... generation in the order of EDTA > 1,10-phenanthroline > DTPA > deferoxamine. Oxygen consumption measurements indicated that ...

No FAQ available that match "deferoxamine"

No images available that match "deferoxamine"